Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing

Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.

Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.